News Archive http://egalet.investorroom.com/ Egalet Receives Complete Response Letter from U.S. Food and Drug Administration for Prior Approval Supplement for 10 mg and 15 mg Dosage Strengths of OXAYDO http://egalet.investorroom.com/2017-06-20-Egalet-Receives-Complete-Response-Letter-from-U-S-Food-and-Drug-Administration-for-Prior-Approval-Supplement-for-10-mg-and-15-mg-Dosage-Strengths-of-OXAYDO Tue, 20 Jun 2017 09:06:00 -0400 http://egalet.investorroom.com/2017-06-20-Egalet-Receives-Complete-Response-Letter-from-U-S-Food-and-Drug-Administration-for-Prior-Approval-Supplement-for-10-mg-and-15-mg-Dosage-Strengths-of-OXAYDO Egalet Partners with Ascend Therapeutics® U.S., LLC to Co-Promote SPRIX® Nasal Spray http://egalet.investorroom.com/2017-06-07-Egalet-Partners-with-Ascend-Therapeutics-R-U-S-LLC-to-Co-Promote-SPRIX-R-Nasal-Spray -- 37 Ascend Therapeutics women's health specialty sales representatives to call on 9,000 women's healthcare practitioners -- Wed, 07 Jun 2017 06:02:00 -0400 http://egalet.investorroom.com/2017-06-07-Egalet-Partners-with-Ascend-Therapeutics-R-U-S-LLC-to-Co-Promote-SPRIX-R-Nasal-Spray Egalet Announces ARYMO® ER Added to Large Payer Formulary http://egalet.investorroom.com/2017-06-06-Egalet-Announces-ARYMO-R-ER-Added-to-Large-Payer-Formulary Tue, 06 Jun 2017 06:02:00 -0400 http://egalet.investorroom.com/2017-06-06-Egalet-Announces-ARYMO-R-ER-Added-to-Large-Payer-Formulary Egalet Announces Issuance of New U.S. Patent for Guardian™ Technology http://egalet.investorroom.com/2017-06-05-Egalet-Announces-Issuance-of-New-U-S-Patent-for-Guardian-TM-Technology -- Patent covers combination products with precise drug delivery properties -- Mon, 05 Jun 2017 06:02:00 -0400 http://egalet.investorroom.com/2017-06-05-Egalet-Announces-Issuance-of-New-U-S-Patent-for-Guardian-TM-Technology Egalet Announces Results of ARYMO® ER Harm Reduction Modeling Analysis http://egalet.investorroom.com/2017-05-18-Egalet-Announces-Results-of-ARYMO-R-ER-Harm-Reduction-Modeling-Analysis -Results suggest that replacement of non-abuse-deterrent, extended-release morphine with ARYMO ER could lead to potential reductions in opioid abuse-related events- Thu, 18 May 2017 16:02:00 -0400 http://egalet.investorroom.com/2017-05-18-Egalet-Announces-Results-of-ARYMO-R-ER-Harm-Reduction-Modeling-Analysis